• News
  • BioTech

DexCom cited as bellwether

CNBC stock commentator Jim Cramer on Friday cited San Diego’s DexCom Inc. (Nasdaq: DXCM) as a bellwether for the stock market, which should go into a turnaround on Wall Street within the next year.

In an interview with TheStreet, Cramer said DexCom had a “disruptive” diabetes monitoring system that has been grabbing an increasingly large part of the market. But he said the stock price has plummeted recently because investors have been focusing more on earnings per share instead of cash flow.

Cramer said the main reason DexCom’s earnings have weakened is that it has been adding more salespeople, which will help generate more revenues. He said if the stock starts bouncing back, it could bode well for similar stocks, signaling that investors are once again focusing on companies’ broader fundamentals.

DexCom shares, which briefly crested above $49 in early March, were selling at $32.45 at noon on Wall Street on Friday, after gaining a boost from Cramer's comments.

User Response
0 UserComments

Dexcom Inc.

Company Website

5555 Oberlin Dr.
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Chg %Chg
High Low
- 1.27%

Insider Trade Data

Date Insider Shares Type Value
10/20/2015 Balo, Andrew K 4,538 Sell $369,670
10/19/2015 Roper, Jess 7,000 Sell $583,573
10/19/2015 Roper, Jess 6,000 Exchange $58,800
10/15/2015 Gregg, Terrance H 15,000 Sell $1,168,796
10/08/2015 Lister, John 2,750 Sell $211,748

Dexcom Inc. Executive(s):

Terrance Gregg

  • Chief Executive Officer, Director

Kevin Sayer

  • Director, President

Patrick Murphy

  • Assist. General Counsel